logo
  • About us
    • The Company in brief
    • Strategy
    • Market
    • Organisation
      • Management
      • Board of Directors
  • Our Drug Projects
    • Science
    • Pipeline
    • Disorders
      • Primary Biliary Cholangitis (PBC)
      • Hepatic Encephalopathy (HE)
  • Investors
    • Financial Reports and Presentations
    • Corporate Governance
    • General meetings
    • Calendar
    • Press Releases
  • Media
    • Press Releases
    • Subscribe
  • Contact

Extra General Meeting, August 2022

August 10, 2022

An extraordinary general meeting was held on Wednesday 10 August 2022.

Documents

  • Notice to attend EGM 2022
    July 5, 2022 English
  • Kallelse till extra bolagsstämma 2022
    July 5, 2022 Svenska
  • Postal voting form (EGM)
    July 5, 2022 English
  • Formulär för poströstning (EGM)
    July 5, 2022 Svenska
  • Power of attorney form (EGM)
    July 5, 2022 English
  • Fullmaktsformulär (EGM)
    July 5, 2022 Svenska
  • Investors
    • Financial Reports and Presentations
    • Corporate Governance
    • General meetings
    • Calendar
    • Press Releases

CONTACT

Anders Karlsson
Chief Executive Officer
Phone +46 70 – 918 00 10
[email protected]

All contacts

VISITING ADDRESS

Karolinska Institutet Science Park
Fogdevreten 2
SE – 171 65 Solna
Sweden

COMPANY INFORMATION

Umecrine Cognition AB
Registered office in Umeå
Reg no 556698-3655

  • Cookies
  • Privacy Policy